Theranostic nuclear medicine has the potential to transform cancer care, but patient access is being stalled because health systems struggle to accurately assess its cost-effectiveness, a University of Queensland study has found.
We spoke to AdvanCell’s Chief Scientific Officer, Dr Simon Puttick, about their partnership over the years with AIBN to drive the next generation of cancer therapies.
A novel cutting-edge technology is accelerating the development of next-generation cancer treatments, with AIBN now home to an AdvanCell Lead-212 generator.
The long-standing partnership between AIBN and Clarity Pharmaceuticals continues to thrive with the signing of a brand-new Supply Agreement for radionuclide, Copper-64.
Molecular radiotherapy (MRT) involves targeted delivery of ionising radiation to trigger localised cell death. Targeted irradiation is achieved using alpha (α) or beta (β-) emitting radionuclides that are incorporated into a radiopharmaceutical.
AIBN researcher Dr Nick Fletcher has won an Advance Queensland Industry Research Fellowship to explore localised cell death and the immune response to cancer.
